Neuroblastoma Biology Study
N2004-05: Neuroblastoma Biology Study
1 other identifier
observational
1,000
2 countries
17
Brief Summary
Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma to improve the ability to follow the response of tumor cells to therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2011
Longer than P75 for all trials
17 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2011
CompletedFirst Submitted
Initial submission to the registry
April 26, 2012
CompletedFirst Posted
Study publicly available on registry
April 30, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2099
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2099
March 23, 2026
March 1, 2026
88.5 years
April 26, 2012
March 19, 2026
Conditions
Eligibility Criteria
Neuroblastoma patients from various NANT sites.
You may qualify if:
- Patients must be greater than or 31 days of age.
- Patients must have had a diagnosis of high risk neuroblastoma either by histological verification of neuroblastoma and/or demonstration of tumor cells in the bone marrow with increased urinary catecholamines.
- All patients with refractory or recurrent high risk neuroblastoma at NANT institutions are eligible regardless of disease status (including no measurable or evaluable tumor) as long as they undergo a disease evaluation and appropriate samples are submitted.
- Additionally, all patients with high risk neuroblastoma without relapse treated at a NANT institution are eligible if undergoing a disease evaluation, as long as Children's Oncology Group specimens are prioritized.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (17)
Children's Hospital Los Angeles
Los Angeles, California, 90027-0700, United States
Lucille Salter Packer Children's Hospital, Stanford University
Palo Alto, California, 94305, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94115, United States
Children Hospital of Colorado
Aurora, Colorado, 80045, United States
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
Atlanta, Georgia, 30322, United States
University of Chicago, Comer Children's Hospital
Chicago, Illinois, 60637, United States
Children's Hospital Boston
Boston, Massachusetts, 02115, United States
C.S Mott Children's Hospital
Ann Arbor, Michigan, 48109, United States
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229-3039, United States
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104-4318, United States
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
University of Texas Southwestern
Dallas, Texas, 75235, United States
Cook Children's Medical Center - Fort Worth
Fort Worth, Texas, 76104, United States
Seattle Children's Hospital
Seattle, Washington, 98105, United States
Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
Biospecimen
The biospecimen includes blood and bone marrow and their derivatives (e.g., DNA, RNA, plasma, lymphocytes) as well as tumors.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Shahab Asgharzadeh, MD
Children's Hospital Los Angeles
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 26, 2012
First Posted
April 30, 2012
Study Start
July 1, 2011
Primary Completion (Estimated)
December 1, 2099
Study Completion (Estimated)
December 1, 2099
Last Updated
March 23, 2026
Record last verified: 2026-03